Company & Sponsor Intelligence
State University of New York at Buffalo
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials7
Recruiting3
Completed4
Countries1
Therapeutic footprint
adhddementia_otherout_of_scopeparkinsons
Indexed studies
NCT01496183Metabolic Effects of Olanzapine in Healthy Males
out_of_scope · United StatesNA
out_of_scope · United StatesNA
NCT05762796Neuromodulation and Neuroimaging in Older Children With Mild Traumatic Brain Injury
dementia_other · United StatesNA
dementia_other · United StatesNA
NCT05387889Piloting Mindfulness Meditation Program for Underserved Racial Minority Adults With Pulmonary Hypertension
out_of_scope · United StatesNA
out_of_scope · United StatesNA
NCT06339034Repurposing Lithium for Parkinson's Disease: a RCT
parkinsons · United StatesPHASE1, PHASE2
parkinsons · United StatesPHASE1, PHASE2
NCT06108297Lithium Long COVID Dose-finding Study
out_of_scope · United StatesPHASE1
out_of_scope · United StatesPHASE1
NCT00918567Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD
adhd · United StatesPHASE4
adhd · United StatesPHASE4
NCT07403539Speech Learning and Speech Production in Parkinson's Disease
parkinsons · United StatesNA
parkinsons · United StatesNA
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →